Multiple Myeloma Hub

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What are the initial data of dara-CyBorD in patients with extramedullary disease?In this podcast, Beksac discusses their poster presented at ASH 2022 entitled: Efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease: a European Myeloma Network study. Beksac outlines the methods and motivations for this phase II open-label study, including the unmet need for patients with para-skeletal plasmacytomas, and concludes by discussing the study results in terms of progression-free survival, safety, and efficacy, and comparing these results with the previous LYRA study. Hosted on Acast. See acast.com/privacy for more information.

Roman Hájek, from the University of Ostrava, discusses the benefits of isatuximab-based combinations in treating relapsed multiple myeloma patients refractory to lenalidomide-based therapy. The focus is on the efficacy of isatuximab with carfilzomib and dexamethasone, highlighting the role of immunomodulatory agents in improving outcomes.

Experts discuss integrating BCMA-directed agents in MM treatment, challenges of CAR T-cell availability, potential of bispecific therapies, and ADCs. Emphasis on managing keratopathy, high response rates with combination therapies, and the importance of evaluating BCMA-directed agents in earlier lines of therapy.

During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that also featured María-Victoria Mateos, Nina Shah, Paul Richardson, and Elena Zamagni. The topic of this discussion was “The role of consolidation after autologous stem cell transplantation”, which was identified as an unmet educational need within multiple myeloma treatment.Gertz begins the discussion by explaining that patients often have confusion over what consolidation therapy is and when it can be used. Mateos then discusses how the number of induction therapy cycles a patient receives can affect the use of consolidation. Richardson talks about the STAMINA trial and how tolerability posttransplant can affect treatment choices, with Shah commenting on the difficulty of replicating trials in the real-world setting. The committee then discuss how historically in trials, the same drug that was used in induction is used as consolidation, and what the potential results would be if a different drug was used for consolidation. Hosted on Acast. See acast.com/privacy for more information.

Experts Roberto Mina and Andrzej J. Jakubowiak discuss the pros and cons of bispecific antibodies for multiple myeloma, highlighting MajesTEC-1 and MagnetisMM-1 trials, efficacy, response rates, challenges like infection risks, comparison to CAR T-cell therapies, and sequencing of therapies in myeloma treatment.

During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, How can bispecific antibodies be combined with monoclonal antibodies to treat relapsed/refractory multiple myeloma?Mateos begins by giving an overview of the bispecific antibodies, talquetamab and teclistamab. These antibodies have been investigated in combination with daratumumab in two clinical trials; Mateos provides a summary of the results of these trials, including the safety and efficacy data. Hosted on Acast. See acast.com/privacy for more information.

Experts Jacob Laubach and Peter Voorhees discuss the impact of Daratumumab as maintenance therapy for transplant-eligible patients with newly diagnosed multiple myeloma. They highlight findings from the GRIFFIN and CASSIOPEIA trials, showing enhanced response rates, minimal residual disease negativity, and improved progression-free survival. The podcast explores the benefits of incorporating Daratumumab into treatment regimens and its role in enhancing overall outcomes for multiple myeloma patients.

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-la-Neuve, BE and Noopur Raje, Massachusetts General Hospital, Boston, US. In this podcast, they discuss the topic: Managing infections with novel immunotherapies: Prevention, treatment, and impact on the quality of life of patients with multiple myeloma.Raje and Delforge discuss the management of infections with novel immunotherapies, including: monoclonal antibodies, antivirals, risk of infection, intravenous immunoglobulin, and the impact of COVID-19. This podcast closely links to our latest editorial theme, in which the Multiple Myeloma Hub explores how to manage adverse events from novel agents, with our first article examining proteasome inhibitors and cardiovascular events. Hosted on Acast. See acast.com/privacy for more information.

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma?This podcast captures the roundtable discussion with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University (Paris, FR), María-Victoria Mateos, University Hospital of Salamanca (Salamanca, ES), and Sagar Lonial, Winship Cancer Institute of Emory University (Atlanta, US), and includes the concluding remarks of the Satellite Symposium as a whole. Hosted on Acast. See acast.com/privacy for more information.

During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: Treating elderly and frail patients with MM: Cure versus disease control.In this podcast, Rajkumar discusses the current standard of treatment for elderly, frail patients (VRd−bortezomib, lenalidomide, dexamethasone) and regimens that are currently being tested across various clinical trials to improve upon this standard, such as replacement of bortezomib with carfilzomib or daratumumab, and quadruplet combinations. He then discusses if a cure is really feasible for MM, and highlights some key considerations for a true cure; when treatment is given for a finite time and the disease never returns. He concludes with his recommendations for assessing MM cure in future trials. Hosted on Acast. See acast.com/privacy for more information.